It is the consensus opinion of the medical oncology reference committee that PACLItaxel 3 weekly is not considered best practice for this patient population.
Treatment Schedule Summary
||8 mg/kg (loading dose only); 6 mg/kg (subsequent doses)
Frequency: every 21 days
Cycle: 4 ( then continue TRASTUZUmab for an additional 13 cycles - total TRASTUZUmab treatment to equal 52 weeks )
"ECOG 1199r evaluated paclitaxel and docetaxel in the adjuvant setting following 4 cycles of doxorubicin/cyclophosphamide. 4950 patients were randomised to 1 of 4 arms with 3 weekly paclitaxel (3 hour infusion) considered the reference regime – weekly paclitaxel, 3 weekly docetaxel and weekly docetaxel. The results of this trial demonstrated superiority for weekly paclitaxel (DFS/OS) and 3 weekly docetaxel (DFS).
With at least 2 studies in the metastatic setting supporting the superiority of the weekly paclitaxel regime (RR/DFS/OS) it was considered that 3 weekly paclitaxel is an inferior regime in the treatment of breast cancer and should not be used in the adjuvant setting. If a 3 weekly regime is preferable then consideration should be given to a docetaxel containing regime."